| Financing threshold: | €1,250,316 |
|---|---|
| Maximum issue size: | €1,349,919 |
| Invested so far: | €435,471.66 |
Breakthrough in hereditary cancer diagnostics: Lynsight’s patented DiagMMR is the unique tumor-independent technology for detecting Lynch syndrome, the most common hereditary cancer syndrome.
Advanced stage with clear regulatory path to FDA marketing authorization: The technology has already been verified in Finland with 94% accuracy. U.S. validation studies with leading cancer hospitals are set for 2026, with FDA clearance expected in early 2027, enabling rapid entry into the U.S. market.
1:1 co-financing highlights institutional trust: Business Finland (Finland’s national innovation and funding agency) is matching the €1.25 million equity raise with a 7-year loan at 1% interest. This commitment doubles investor leverage and confirms Lynsight’s strategic importance in the Finnish life sciences sector.
Large, recurring global market: Millions of people worldwide have Lynch syndrome, yet most remain undiagnosed. With a per-test price of around $3,000, Lynsight targets a €1+ billion global market with recurring demand driven by new cancer cases and family cascade testing.
Strong leadership and scientific foundation: A world-class team combines decades of research from the University of Helsinki with proven business execution under CEO Niklas Lahti, positioning the company for international growth.
“Our mission is to bring clarity and prevention to families living with hereditary cancer risk. With DiagMMR, clinicians can identify Lynch syndrome before cancer occurs, enabling early action and saving lives. This funding round marks the final step towards regulatory approval and U.S. market entry, turning decades of research into accessible, life-changing diagnostics. Join us in shaping the future of preventive cancer care.”
Niklas Lahti, CEO of Lynsight Oy
Every year, millions of people develop cancers that could have been prevented with timely detection of the inherited risk. Lynch syndrome, the world’s most common hereditary cancer syndrome, affects about one in 279 people, yet more than half of individuals with the condition remain undiagnosed. Current genetic tests and tumor-based methods often produce disease-indicating but inconclusive results, leaving a major gap in preventive care.
Lynsight is a Finnish diagnostics company transforming the hereditary cancer market through functional testing. Spun-off from long-term research at the University of Helsinki on DNA mismatch repair (MMR) mechanism and the health impact of MMR deficiency, the company has developed DiagMMR, the functional test that can reliably identify Lynch syndrome before cancer develops.
Unlike conventional methods that rely on tumor samples and genetic sequencing, DiagMMR measures DNA repair function directly in a patient’s normal cells. This functional approach offers a unique path to early detection, enabling preventive care and guiding those at risk to regular follow-up.
Lynsight’s mission is to empower families and healthcare professionals to make better-informed decisions for cancer prevention. The company is currently advancing through the regulatory process, with commercialization in the U.S. planned for 2027.
To reach this milestone, Lynsight is raising €1.25 million in equity, matched by €1.25 million in Business Finland loan financing, to complete clinical validation studies and prepare market entry.
With a patented technology, strong international partnerships, and a clear route to market, Lynsight is positioned to transform hereditary cancer diagnostics and capture a leading role in a billion-euro global market.
1. Sample collection: A small skin biopsy (2 mm) is taken from the patient’s forearm by a healthcare professional. This is a quick and minimally invasive procedure.
2. Functional analysis: In Lynsight’s laboratory, primary cells from the sample are cultured. DiagMMR then measures how effectively the mismatch repair (MMR) proteins function, directly assessing the patient's inherited MMR repair capability.
3. Clear result: The result is interpreted using a mathematical algorithm and classified as either MMR proficient or deficient. If proficient, Lynch syndrome can be excluded. If deficient, Lynch syndrome is confirmed, enabling preventive care and follow-up for the patient and their family.
Lynsight’s core innovation, DiagMMR, is a patented technology that revolutionizes how hereditary cancer risk, Lynch syndrome, is detected. The test measures the functionality of the DNA mismatch repair (MMR) system, the body’s natural “spellchecker” that corrects errors when cells divide. If this repair mechanism fails, errors accumulate, leading to cancers such as colorectal, endometrial, or ovarian.
Current testing methods rely on tumor samples and germline sequencing. Both approaches often face challenges, especially in interpreting the results. Tumor findings can be suggestive of Lynch syndrome but are generally not specific for it. Germline sequencing may fail to detect a pathogenic mutation, even when clinical suspicion is high, leaving results inconclusive and conflicting with other patient data. Confirming pathogenicity also requires complex bioinformatics. DiagMMR overcomes these limitations by providing a direct result, showing whether the inherited MMR mechanism is functioning or not.
For patients, DiagMMR offers clarity and peace of mind through early detection of hereditary cancer risk and enables effective treatments and follow-ups.
For clinicians, it provides a reliable, easy-to-interpret tool to support care decisions instead of uncertain results.
For healthcare systems, DiagMMR enables targeted interventions for the right at-risk individuals, reduces unnecessary testing, and improves resource allocation, creating long-term economic and clinical value.
Lynsight’s business model is built on the commercialization of its patented DiagMMR technology as a premium diagnostic service. Revenue will be generated on a per-test basis, through a CLIA-certified central laboratory in the United States, where physicians and hospitals can order the test directly.
The commercial launch will begin immediately after FDA marketing authorization, with tests sold out-of-pocket to early adopters. This phase will generate initial revenue and real-world data to support reimbursement applications. Once reimbursement is secured from major U.S. health insurance providers, Lynsight will unlock large-scale adoption through hospitals and cancer centers.
This reimbursement-driven model is highly scalable. Once coverage is established, the test can be integrated into standard healthcare diagnostics, leading to predictable and recurring revenue. With a benchmark price of $3,000 per test, even modest adoption among high-risk cancer patients and their families represents substantial revenue potential.
Lynsight’s long-term strategy includes expanding DiagMMR testing to partner laboratories and hospital networks through licensing or reference-lab agreements, creating additional revenue streams with minimal operational cost.
The model combines a clear regulatory pathway, strong unit economics, and recurring demand from a guideline-based medically necessary testing market, creating a sustainable foundation for high-margin growth.
Lynsight operates in the fast-growing field of hereditary cancer diagnostics, with Lynch syndrome as its entry point. Lynch syndrome affects around 1 in 279 people worldwide, yet more than half of carriers remain undiagnosed. Globally, hundreds of thousands of new cancer patients each year meet the medical criteria for Lynch syndrome testing, and every confirmed carrier leads to additional family members eligible for testing.
This creates a built-in multiplier effect: each positive diagnosis expands testing demand through cascade screening among relatives. As a result, the total addressable market for DiagMMR includes millions of potential tests annually. Lynsight estimates its initial addressable market at over 45,000 tests per year in the United States, representing a revenue potential of approximately $130 million. The broader global opportunity exceeds €1 billion, driven by patients and families at risk of Lynch syndrome in developed countries.
Current diagnostic pathways rely on tumor tissue analysis and genetic sequencing, which often produce inconclusive results and require complex interpretation. DiagMMR complements these methods by offering a tumor-independent, functional approach that directly measures DNA mismatch repair capability. As the first test of its kind, DiagMMR helps resolve diagnostic uncertainty and fills a clear gap in the hereditary cancer testing landscape.
With patented technology, high diagnostic accuracy, and active discussions underway with leading cancer hospitals, including Mayo Clinic, City of Hope, and Fox Chase Cancer Center, Lynsight is well positioned to capture a significant share of this rapidly growing, guideline-driven global market.
The Sustainable Development Goals (SDGs or 'Global Goals') are part of the UN 2030 Agenda for Sustainable Development and constitute the international framework for sustainable development until 2030. These SDGs are intended to put an end to poverty, inequality, and climate change.
Lynsight’s mission goes beyond diagnostics - it is about enabling prevention, equity, and innovation in global healthcare. By improving early cancer detection and building scalable, science-based solutions, the company actively supports several of the United Nations Sustainable Development Goals.
Lynsight directly contributes to SDG 3 by improving early detection and prevention of hereditary cancers. Through its DiagMMR test, the company enables reliable identification of Lynch syndrome before cancer develops, allowing families and healthcare providers to take preventive action. Early diagnosis not only saves lives but also reduces healthcare costs by shifting focus from treatment to prevention, promoting longer, healthier lives for patients worldwide.
By developing a proprietary diagnostic technology based on decades of scientific research, Lynsight advances innovation in the life sciences sector. The company’s functional testing approach bridges cutting-edge molecular biology and practical clinical application, setting a new standard in hereditary cancer diagnostics. Its scalable laboratory model also strengthens healthcare infrastructure by integrating advanced diagnostics into existing care pathways.
Early and accessible diagnosis helps reduce inequalities in healthcare. Lynsight’s test can be performed from a simple skin biopsy, eliminating dependence on tumor samples or complex sequencing facilities. This enables broader access to reliable diagnostics, even in settings where advanced infrastructure is limited. By empowering families across regions and socioeconomic backgrounds to understand and manage their cancer risk, Lynsight supports a more equitable global healthcare system.
Chief Executive Officer
Niklas Lahti has led Lynsight since 2022, following five years as CFO. He holds a Master’s degree in Finance from Aalto University and previously advised on M&A and capital raising in corporate finance. Combining financial expertise with strategic leadership, Lahti has guided Lynsight through major milestones: raising over €7 million in equity, securing a strategic partnership with U.S.-based diagnostics company New Day Diagnostics, building relationships with multiple leading hospital networks, and advancing toward FDA clearance and U.S. market entry. He is a visionary CEO focused on bold decision-making, strategic growth, and long-term value creation, positioning Lynsight for successful international growth.
Chief Scientific Officer
Doctor Minttu Kansikas co-invented the DiagMMR technology and brings over a decade of research experience in molecular genetics, with a focus on Lynch syndrome and DNA mismatch repair (MMR). Her work at the University of Helsinki laid the scientific foundation for Lynsight’s diagnostic innovation. As CSO, she leads R&D, technology validation, and clinical collaborations, and heads Lynsight’s laboratory team in Finland, ensuring scientific integrity, regulatory readiness and clinical impact across all aspects of product development and clinical implementation.
Head of Culture and Communication
Philippe Arnez leads business development, communications, and organizational strategy at Lynsight. Trained at ETH Zürich in Management, Technology and Economics, and with a decade of experience in international procurement and leadership, he has played a key role in aligning company culture, investor communication, and strategic growth. His cross-disciplinary approach bridges science, business, and people which is essential for Lynsight’s global scaling.
Chairman of the Board
Todd Snowden brings over 30 years of strategic, operational, and commercialization expertise in life sciences to his role as Chairman of the Board at Lynsight. He holds a Bachelor of Science in Bioengineering and Pre-Medicine from the Catholic University of America and has led and advised numerous diagnostic and therapeutic ventures across the U.S. and Europe. Snowden served as CEO of PathoGene LLC, a molecular diagnostics company, and is the founder and principal consultant of Ascent Business Advisors, a strategy firm focused on capital raising, product development, regulatory planning, and commercialization in diagnostics, digital health, and medical devices. His experience spans molecular diagnostics, laboratory services, and medical devices, with leadership roles in product development, international sales, and business management.
Board Member
Professor Minna Nyström is the Founder of Lynsight and lead inventor of the DiagMMR test. With over 30 years of pioneering research in Lynch syndrome, DNA mismatch repair, and hereditary cancer genetics at the University of Helsinki, she is recognized as one of the world’s foremost experts in her field. Prof. Nyström continues to guide Lynsight’s scientific vision through her role on the board of directors and by serving as chair of the company’s Clinical Advisory Board.
Board Member
Rolf Ehrnström is a seasoned life sciences executive with over 30 years of experience in R&D leadership, strategic development, and commercialization within the diagnostics and biotechnology sectors. Ehrnström holds an M.Sc. in Biochemistry and Biotechnology from the Royal Institute of Technology in Stockholm. Ehrnström's career includes senior roles at prominent companies such as Amersham Pharmacia Biotech, Dako (acquired by Agilent), and Gyros AB, where Ehrnström served as Vice President of R&D. Ehrnström was also Chief Scientific Officer at Immunovia AB and is currently the CEO and owner of Reomics AB. Ehrnström is additionally a partner at Ventac Partners, A consultancy specialixing in life sciences. As a board member of Lynsight, Ehrnström bring invaluable expertise in R&D, regulatory affairs, and strategic growth, contributing to the company's mission of advancing hereditary cancer diagnostics.
Lynsight Oy is a single Finnish legal entity headquartered in Helsinki. Investors in this funding round will receive direct equity in the parent company, ensuring full transparency and alignment of interests.
Lynsight is raising €1.25 million in equity, matched by a €1.25 million loan from Business Finland, to finance the company’s final steps toward commercialization in the United States.
This structure ensures that every euro invested by private investors is matched 1:1 by public funding, significantly reducing the project’s financing risk while increasing its impact.
Business Finland’s involvement underlines Lynsight’s national importance as a Finnish life sciences innovator and provides non-dilutive leverage to investor capital. The funding combination will cover all operational and regulatory milestones up to FDA market authorization in early 2027, establishing the foundation for the U.S. commercialization and future growth.
With a total of €2.5 million in combined equity and loan funding, Lynsight will be fully financed to reach its FDA approval, launch DiagMMR commercially in the U.S., and prepare for large-scale revenue generation starting in 2027.
Lynsight’s current funding round combines equity capital from investors with strategic public co-financing, ensuring both financial stability and strong leverage on invested capital.
Total financing volume: €2.5 million
| Source | Amount (€) | Type | Purpose | |
|---|---|---|---|---|
| Equity round (current raise) | 1,250,000 | Equity | Completion of FDA validation studies and commercialization preparation | |
| Business Finland loan | 1,250,000 | Debt (7-year term, 1% interest) | Co-financing for R&D validation, scalability, and U.S. market readiness | |
| Total | 2,500,000 |
Lynsight’s pre-money valuation for this funding round is set at €24.2 million, reflecting the company’s advanced development stage, reduced risk profile, and strong commercial potential.
This valuation represents a logical progression from Lynsight’s previous funding round in 2023, which closed at a €19.6 million post-money valuation. Since then, the company has made major advancements:
Completion of successful verification studies in Finland, demonstrating 94% diagnostic accuracy.
Entry into the FDA regulatory approval process with clear regulatory milestones and partnerships in place.
Well-advanced discussions with leading U.S. cancer centers regarding participation in upcoming validation studies and commercialization.
Secured €1.25 million in non-dilutive public funding from Business Finland with highly favourable terms (7 years, 1% interest).
Strategic collaboration with U.S.-based commercial diagnostics laboratory New Day Diagnostics.
Compared with industry peers at similar stages of FDA approval, the valuation remains moderate and justified, offering investors meaningful upside as Lynsight advances toward commercialization.
The valuation also factors in the company’s patent-protected technology, scalable business model, and exit potential within 36–60 months, where a 5 - 10x return can potentially be achievable upon FDA approval and strong market entry when comparing to previous exits that have happened in the field.
Lynsight is raising this funding round to a maximum amount of 1.35 million euros. This will release the Business Finland loan of 1.25 million euros which has already been granted.
Lynsight additionally explores to continue the fundraising process in early 2026 to reach a total amount of 3.0 million euros in equity including the equity raised in this funding round. The funding will allow for completion of FDA marketing authorization, U.S. market entry preparation, and readiness for the next growth phase. The company estimates that the next equity funding round will take place after obtaining FDA clearance.
Lynsight is already in dialogue with potential investors regarding the next funding round and aims to secure a leading international investor, preferably U.S.-based. The target amount of the follow-up round is around 20 million euros, which will be used for market expansion in the United States.
The company believes that this expected funding round will allow the company to scale, reach break-even and ultimately profitability.
In addition to equity funding Lynsight plans to continue exploring non-dilutive funding extensively. Such funding could include both grants and debt instruments.
Lynsight has raised a total of only slightly less than 9 million euros in funding since inception showing remarkable efficiency in the operations of the company. As a result of these funding round the company has a total of 630 shareholders who have supported the company on its growth journey.
All previous convertible bonds have been converted into equity after the last equity raise in 2023.
Investor |
Type of funding |
Year |
Amount |
Pre-money valuation |
|
|---|---|---|---|---|---|
| 1 | Founders |
Founding of company |
2013 | 2,500 € | 2,500 € |
| 2 | Private | Equity | 02.2015 | 300,015.28 € | 2,680,000 € |
| 3 | Private | Equity | 11.2015 | 250,072.16 € | 9,696,169.12 € |
| 4 | Private | Equity | 09.2017 | 290,039.15 € | 7,439,111.40 € |
| 5 | Private | Equity | 08.2018 | 250,021.12 € | 7,808,769.38 € |
| 6 | Private | Equity | 04.2019 | 315,033.37 € | 8,058,790.50 € |
| 7 | Private | Equity | 11.2019 | 100,613.55 € | 8,501,499.90 € |
| 8 | Private | Equity | 09.2022 | 730,001.25 € | 3,001,878.00 € |
| 9 | Current owners | Convertible | 11.2022 | 600,000.00 € | 10,698,053.88 € (CAP) |
| 10 | Current owners | Equity | 03.2023 | 200,000.00 € | 14,030,472.00 € |
| 11 | Springvest | Equity | 03.2023 | 5,401,600.00 € | 14,030,472.00 € |
| 12 | Convertible holders | Conversion of convertible | 04.2023 | 216,470.00 € | - |
| 13 | Convertible holders | Conversion of convertible | 04.2023 | 218,611.00 € | - |
| 14 | Convertible holders | Conversion of convertible | 04.2023 | 117,909.00 € | - |
| Total | 8,992,885.88 € | 19,632,072.00 € |
Lynsight has identified a clear and time-bound path to value realization, typical for MedTech companies approaching regulatory approval.
Trade Sale / Strategic Acquisition
The most likely scenario is a sale to a major diagnostics or healthcare company seeking to expand their portfolios. Market authorization by the FDA will make Lynsight an attractive acquisition target with strong IP and immediate revenue potential.
Merger
A merger with another company represents a viable exit route with potentially significant strategic value. Such a transaction may combine complementary technologies, expand market reach, and accelerate commercialization. Depending on deal structure, a merger may provide liquidity for shareholders while positioning Lynsight within a larger platform for long-term growth.
IPO
An initial public offering could become an attractive option following successful FDA clearance, US market entry, and strong revenue growth. A listing would provide access to significant growth capital, enhance brand visibility, and create liquidity for shareholders, positioning Lynsight strongly for its global expansion..
Expected timeframe
Lynsight has identified that an exit or major liquidity event could occur within the next 36–60 months, most likely between 2029 and 2031, following FDA authorization and early market traction.
Similar exits in the field of diagnostics have offered investors with highly attractive returns. Recent exits in the diagnostics field, which show clear interest of strategic buyers in acquiring leading companies, include:
This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter..
You can reach us by mail, by phone and via our chat.
+358 40 779 5389
In our FAQ section you will find answers to frequently asked questions.
